Cell Surface Bio Unveils VeRSa-Select™: A Breakthrough in Custom Antibody Development

Cell Surface Bio (CSB) has recently launched a groundbreaking service named VeRSa-Select™, aimed at providing scientists with the highest quality custom antibodies available. This innovative service caters to those tackling some of the most challenging and structurally intricate therapeutic targets in biomedical research, including G protein-coupled receptors (GPCRs) and ion channels. Designed to support target validation in drug discovery efforts, VeRSa-Select™ empowers researchers to obtain reliable and effective antibody reagents.

Underpinned by the advanced therapeutic antibody discovery technology developed by its parent company, Integral Molecular, CSB provides access to highly specific and high-affinity reagents that are capable of cross-reacting with various mammalian species such as humans, mice, cynomolgus monkeys, dogs, pigs, ferrets, and marmosets. This broad compatibility is essential for researchers working to validate novel therapeutic targets within diverse disease models before embarking on comprehensive drug discovery campaigns.

Customization and Rigorous Testing

VeRSa-Select™ offers a unique flexibility in its workflows, allowing for customization according to the specific needs of researchers. Key applications available for antibody validation include flow cytometry, immunofluorescence, and immunohistochemistry. Additionally, each antibody undergoes stringent testing against over 6,000 native proteins utilizing the Membrane Proteome Array™, ensuring exceptional specificity and reliability.

In an effort to optimize the consistency and reproducibility of results, CSB provides recombinant cloning for the production of its antibodies, ensuring they are animal-free and maintain batch-to-batch uniformity. This commitment to quality is vital as researchers seek dependable tools to advance their studies in drug development.

Advancements in Antibody Technology

According to Ross Chambers, PhD, the Vice President of Antibody Discovery at Cell Surface Bio, “Therapeutic antibodies have revolutionized medicine, yet most commercially available research antibodies haven’t benefitted from advancements in the field.” He emphasizes that CSB utilizes cutting-edge technologies equivalent to those employed in therapeutic antibody discovery. This includes using virus-like particles and mRNA for presenting native antigens, alongside dependency on evolutionarily divergent species like chickens to generate cross-reactive antibodies that effectively target difficult proteins.

By leveraging these advanced technologies, CSB ensures the smooth validation of new drug targets that previously lacked adequate reagents. The introduction of VeRSa-Select™ is therefore a significant leap forward in the antibody service sector, matching cutting-edge research with the tools necessary for scientific advancement.

Expanding the Antibody Portfolio

In conjunction with its new custom antibody service, CSB also maintains a growing catalog of its premier VeRSaMAb® reagents—Validated, Recombinant, and Specific monoclonal antibodies designed for the study of challenging cell surface proteins and additional targets. With a strong foothold in developing and characterizing antibodies against some of the complex cell surface proteins known, CSB is committed to delivering only the highest quality products to researchers working in the field.

Conclusion

Cell Surface Bio's mission revolves around the dedication to providing researchers with the highest quality antibodies. With over 20 years of experience in the field, CSB recognizes the intrinsic value of a researcher’s time in the lab, making them a trusted partner for scientists navigating the complex landscape of therapeutic target validation. As the launch of VeRSa-Select™ indicates, CSB is not just keeping pace but leading the way in antibody development, positioning itself as an essential resource in the modern landscape of biomedical research.